Research Article

A CASE REPORT OF IFOSFAMIDE INDUCED ENCEPHALOPATHY IN THE MANAGEMENT OF METASTATIC VULVAR LEIOMYOSARCOMA IN NATIONAL HOSPITAL ABUJA

Shagaya Uchechukwu Nneka1, Ayuba Hannatu U2*, Paul Emeka3, Bello Abubakar Mohammed1, Mohammed Nafisah Mamman1, Kwapmi Nicholas N.4, Umar Farouk Dalhat1, Anosike Agbedo1
1 Radiotherapy and Oncology Department, National Hospital Abuja, Nigeria.
2 Radiotherapy and Oncology Department, National Hospital Abuja, Nigeria
3 Radiology Department, National Hospital Abuja, Nigeria.
4 Federal Medical Centre, Jalingo, Taraba State
* Corresponding author: hannatuayuba@gmail.com
Published: Jul, 2025
DOI: 10.67579/njo.2025.ddie0w3q
Pages: 332-336
Views: 247
Downloads: 174

Abstract

Introduction: Ifosfamide induced encephalopathy (IIE) is not a common phenomenon and is under reported in our context. Its incidence ranges between 10 to 40% in developed settings. It comprises of a range of neuropsychiatric conditions such as confusion, disorientation, somnolence, agitation, hallucinations, lethargy, and seizures. With the extensive use of ifosfamide in oncology in the management of sarcomas, lymphomas and gynaecologic malignancies, its toxicity may present a challenge to the management of patients with cancer.


Case Presentation: Here we report a case of metastatic recurrent vulvar leiomyosarcoma in a 48-year-old woman, with no family history of cancer. She was referred after the histopathological assessment of a recurrent lesion in her vulvar associated with abdominal distension, a solitary subcutaneous scalp lesion and multiple subcutaneous metastatic nodular lesions at her back. She was investigated and found to be fit for chemotherapy. She was placed on oral dexamethasone, a proton pump inhibitor and antacids and planned to commence systemic chemotherapy using the Ifosfamide based MAID regimen. On the Day 2 chemotherapy infusion, she developed confusion, loss of consciousness and mutism which she recovered completely from 6 hours after suspension of the chemotherapy and institution of emergency medications.


Conclusion: Clinical practitioners are often unable to identify high-risk patients prior to treatment and the unanticipated development of neurologic symptoms may cause treatment delay, treatment discontinuation, and subsequent disruption of treatment plans. Therefore, a high index of suspicion is important to prevent, identify and manage this condition.


Keywords

Leiomyosarcoma vulvar ifosfamide encephalopathy central nervous toxicity confusion hypoalbuminaemia methylene blue thiamine

References

  1. Yin Lo, Li-Jiuan Shen, Wen-Hwei Chen, Yaa-Hui Dong, Fe-Lin Lin Wu. Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis. www.sciencedirect.com Journal of the Formosan Medical Association. 2016;115, 744e751
  2. Audrea H Szabatura, Frank Cirrone, David Fischer. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. Sage journals. 21(3) https://doi.org/10.1177/1078155214527143
  3. Delépine N, Taillard F, Desbois JG, Cornille H, Delépine G, Jasmin C. CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas. Biomed Pharmacother. 1986;40(5):173-5. PMID: 3098318.
  4. Natcha Stern, Cyril Lervat Anne Sophie, Thomas Ryckewaert, Guillarme Marliot et al. Risk factors for ifosfamide-related encephalopathy (IRE) in sarcoma (S) patients (pts). Journal of Clinical Oncology. 33(15) https://doi.org/10.1200/jco.2015.33.15_suppl.e21523
  5. Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced encephalopathy precipitated by aprepitant: A rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 2017; 8:38-40
  6. Heim, M.E., Fiene, R., Schick, E. et al. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol. 1981;100: 113–116. https://doi.org/10.1007/BF00405909
  7. Klinikum Wels-Grieskirchen. Chemotherapy Protocols 2020 Current Protocols v and Targeted Therapies" 20th Edition April 2000. www.chemoprotocols.eu
How to Cite

Nneka, S. U., U, A. H., Emeka, P., Mohammed, B. A., Mamman, M. N., N., K. N., Dalhat, U. F., & Agbedo, A. (2025). A CASE REPORT OF IFOSFAMIDE INDUCED ENCEPHALOPATHY IN THE MANAGEMENT OF METASTATIC VULVAR LEIOMYOSARCOMA IN NATIONAL HOSPITAL ABUJA. Nigerian Journal of Oncology, 1(2), 332-336. https://doi.org/10.67579/njo.2025.ddie0w3q

S. U. Nneka, A. H. U, P. Emeka, B. A. Mohammed, M. N. Mamman, K. N. N., U. F. Dalhat, and A. Agbedo, "A CASE REPORT OF IFOSFAMIDE INDUCED ENCEPHALOPATHY IN THE MANAGEMENT OF METASTATIC VULVAR LEIOMYOSARCOMA IN NATIONAL HOSPITAL ABUJA," Nigerian Journal of Oncology, vol. 1, no. 2, pp. 332-336, July 2025. doi: 10.67579/njo.2025.ddie0w3q

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles